New MRI scan could spot kidney trouble early in fabry patients
NCT ID NCT05923788
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tested whether a special MRI scan called T1 mapping can detect kidney damage in people with Fabry disease, a rare genetic disorder. Researchers compared MRI results from 70 adults with and without Fabry disease. The goal was to see if this non-invasive scan could help doctors diagnose and monitor kidney problems without needing a biopsy.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- What this could lead to
- If successful, this MRI method could become a non-invasive tool to detect kidney damage earlier in Fabry disease and help guide treatment decisions.
- What could go wrong
- This is a small, completed observational study, not a treatment trial. The MRI technique may not prove accurate enough for routine clinical use, and results may not apply to all patients.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Participants
-
70 people
The number who actually took part.
- Started
-
Aug 2023
- Finished
-
Apr 2026
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Patient with confirmed Fabry disease Or Control patients: Patients undergoing renal functional exploration for a reason other than Fabry disease, amyloidosis, hemochromatosis * Adult patient * Patient informed of the study and agree to participate * Patient affiliated to a social security or beneficiaries of a similar scheme Exclusion Criteria: * Weight \> 130 kg * kidney transplant, * polycystic kidney disease, * Pregnant, parturient or breastfeeding * Contraindications to MRI * Subject participating in another research including an exclusion period still in progress at inclusion * Persons deprived of their liberty by a judicial or administrative decision, * Adults subject to a legal protection measure (safeguard measure, guardianship, curators)
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Fabry disease are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Hopital Edouard Herriot
Lyon, 69003, France
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a One-Time gene therapy fix fabry disease for years?
- Can a new pill stop fatty buildup in fabry disease?
- Gene Therapy's lasting promise: can one infusion safely control fabry disease for years?
- Can early enzyme therapy save kidneys in fabry disease?
- Can continued lucerastat access help fabry patients?
- Can a single gene infusion rewrite the story of fabry disease?